Targeting the PD-1/PD-L1 Axis in Non-Small-Cell Lung Cancer

The last decade has witnessed rapid advances in the discovery and development of immune checkpoint inhibitors in cancer medicine, particularly drugs targeting programmed cell death 1 and programmed cell death ligand-1 in non-small cell lung cancer. The proven antitumor efficacy coupled with low rates of drug-related toxicities observed, albeit idiosyncratic, with these novel immunotherapeutics, have led to the registration of multiple programmed cell death 1 and programmed cell death ligand-1 inhibitors, such as nivolumab, pembrolizumab and atezolizumab, in second-line advanced non-small cell lung cancer, while durvalumab and avelumab are in late phase clinical testing.

Source: Current Problems in Cancer - December 22, 2016 Category: Cancer & Oncology Authors: Rajiv Kumar, Dearbhaile Collins, Saoirse Dolly, Fiona McDonald, Mary E.R. O ′Brien, Timothy A. Yap Tags: Review article Source Type: research